Learn more about our WAVEsystem and its applications

  • TechNote 1

    Sensitive kinetic analysis of small molecules binding to large drug targets

    In this TechNote we show how the WAVEsystem can be used to accurately monitor binding kinetics of large target-to-analyte molecular weight (MW) ratios (>300:1), thanks to the expanded sensing field over which the Grating-Coupled Interferometry (GCI) technology measures for high sensitivity.

  • TechNote 3

    Fast off-rates: weak binders, strong data

  • TechNote 5

    Low signal kinetics: going below Rmax 1

  • TechNote 7

    Binding kinetics of a GPCR

  • TechNote 8

    Small molecules can‘t hide anymore

  • TechNote 10

    Affinity and kinetics of antibodies in serum

  • TechNote 11

    Quick characterization of binding onto unpurified GPCRs

    In this TechNote, we show how the WAVEsystem can be used for the kinetic analysis of G-protein binding onto detergent-solubilized, unpurified GPCRs. By shortening a typical 10-step purification process, this method requires significantly less material (30mL of cell culture) and less time (less than 1 hour), thereby offering an alternative for screening purposes at an early stage of the drug discovery process involving membrane proteins.

  • TechNote 12

    Antibody characterization from COVID-19 patient plasma binding to SARS-CoV-2 antigens

    In this TechNote, we show how the WAVEsystem can be used for the characterization of binding affinity and kinetics of antibodies raised against SARSCoV-2 in clinical human blood plasma samples. With innovative disposable, no-clog microfluidics and high sensitivity, the WAVEsystem opens the door for antibody characterization directly from clinical blood plasma samples. The methods described here are also compatible with high concentrations of serum
    and plasma of SARS-CoV-2 patients’ samples.

  • TechNote 14

    Shedding light on sybodies binding onto SARS-CoV-2 spike RBD

    In this TechNote we show how the WAVE system can be used to understand the binding dynamics of Sybody® candidates to the receptor binding domain (RBD) of SARS-CoV-2, both provided by Linkster Therapeutics AG and the University of Zürich. With high sensitivity and robust microfluidics, the WAVEsystem is suitable for competition assays, confirming and enriching ELISA data. By providing a rapid kinetic characterization for inhibition assays,
    with ACE2 kindly provided by leadXpro, the WAVE is accelerating the development of therapeutics
    against SARS-CoV-2.